Volume : 2, Issue : 9, SEP 2016

ACID DIETARY AS DIABETOGENIC RISK FACTORS

Sharofova Mizhgona, Nuraliev Yusuf, Ganiev Khurshed, Suhrobov Parviz, Zubaydova Tojinisso, Samandarov Nasrullo, Mirshahi Massoud

Abstract

Investigation of diabetogenic impact of acid dietary were performed on rabbits (n=72) in several groups, control and treated animal by freshly natural lemon juice (LJ) 2 and 5 ml / kg body weight once daily intragastric administered for 2 weeks. In parallel, Helichrysum Thianschanicum Regel soluble extract (HTRSE 2 ml / kg) was used as an antidiabetic plant. In all experiments, Insulin resistance (IR) and glucose tolerance tests (GT) were achieved.

It was found that under the influence of LJ dietary, I) pH indicator decreased respectively 6.2 % for blood and 16.9 % for urine (P < 0001). II) Blood glucose level and HbA1c were increased 55.0% and 51.2% respectively (P < 0001). III) by IR analysis, the hypoglycemia was noted 86.1% after 45 min and 84.2% after 90 min. IV) by GT test, glycaemia increased from 23.6% to 60.2% for 2ml/Kg of acid diets (P < 0001) as well as 37.7% to 67.2% for 5 ml/kg after 60 to 180 mins (P < 0001) respectively. V) After two weeks of diets, the alteration of liver and kidney biomarkers such as ALAT, ASAT, as well as uric acid, creatinine and Urea respectively were observed. VI) When the pre-diabetic animals dieted by LJ and HTRSE (pH=6.7) simultaneously, all pathologic indicators were normalized. In conclusion pre-diabetes stage as a consequence of acid dietary is associated with decrease of blood and urine pH and alteration of liver and kidney function. HTSE as non-acid dietary had shown an anti-diabetic effect.

Article : Download PDF

Cite This Article

Article No : 15

Number of Downloads : 926

References

1- American Diabetes Association®, www.diabetes.org/diabetes-basics/statistics.
2- Dey , L., Attele, AS. and Yuan, CS. (2002). Alternative therapies for type 2 diabetes.
Altern Med Rev, 7(1), p. 45-58.
3- Giovannini, P., Howes, MJ. and Edwards, SE. (2016). Medicinal plants used in the traditional
management of diabetes and its sequelae in Central America: A review. J
Ethnopharmacol. 26; 184, p. 58-71. doi: 10.1016/j.jep.2016.02.034.
4- Caspary, WF. (1978). Sucrose malabsorption in man after ingestion of alphaglucosidehydrolase
inhibitor. Lancet, 1, p. 1231–1233.
5- Shepherd, PR. and Kahn, BB. (1999). Glucose transporters and insulin action--
implications for insulin resistance and diabetes mellitus. N Engl J Med, 341, p.
248–257.
6- Curry, DL. and Li, CH. (1987). Stimulation of insulin secretion by beta endorphin (1-27
and 1-31). Life Sci, 40, p. 2053–2058.
7- Welihinda, J., Arvidson, G., Gylfe, E., Hellman, B. and Karlsson, E. (1982). The insulin-
releasing activity of the tropical plant momordica charantia. . Acta Biol Med Ger,
41, p. 1229–1240.
8- Li, CH, Chung, D and Doneen, BA. (1976). Isolation, characterization and opiate activity
of b-endorphin frohuman pituitary glands. Biochem Biophys Res Commun, 72, p.
1542–1547.
9- Viveros, OH., Diliberto, EJ., Hazum, E. and Chang, KJ. (1979). Opiate-like materials
in the adrenal medulla: evidence for storage and secretion with catecholamines. Mol
Pharmacol. 16, p. 1101–1108.
10- Wolff, SP. (1993). Diabetes mellitus and free radicals. Free radicals, transition metals
and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med
Bull, 49, p. 642–652.
11- El-Abhar, HS. and Schaalan MF. ( 2014) Phytotherapy in diabetes: Review on potential
mechanistic perspectives, World J Diabetes. 15; 5(2), p. 176–197. doi:
10.4239/wjd.v5.i2.176
12- Sina A A. (2014). The Canon of Medicine, Book Three, Part One. Dushanbe: Donish,
– pp.1000, (In Russian).
12- Nuraliev, YN, Ganiev, HA, Sharofova, MU. Et al. (2013). Hepatotoxic
diabetogenicity action of lemon fruit at the junction of Avicenna medicine and modern
medicine, Reviews of clinical pharmacology and drug therapy, Special Issue, 11, p.
114-115.
13- Sharofova, MU. and Nuraliev, YN. (2013). Questions of etiopathogenesis and treatment
of diabetes in the medicine of Avicenna and their significance for modern medicine,
Reviews of clinical pharmacology and drug therapy, St-Petersburg, 11, p. 153-
155.
15- Blau, NF. (1923). The amino acid nitrogen of the blood, J. Biol. Chem. 9, p. 873-879.
16- Yoo, TW., Sung, KC, Shin HS., et al. (2005). Relationship between serum uric acid concentration
and insulin resistance and metabolic syndrome. Circulation Journal, 69, no.
8, p. 928–933
17- Shankar, A, Klein, R., Klein, BK. and Nieto, J. (2006 ). The association between
serum uric acid level and long-term incidence of hypertension: population-based
cohort study, Journal of Human Hypertension, 20, no. 12, p. 937–945.
18- Klein, R., Klein, BE., Cornoni, JC., Maready, J., Cassel, J. C . and Tyroler H. A. (1973)
Serum uric acid, Its relationship to coronary heart disease risk factors and cardiovascular
disease, Evans County, Georgia, Archives of Internal Medicine, 132, no. 3, p.
401–410,
19- Sundstrom, J., Sullivan L.,. Agostino R. B. D, Levy D., Kannel W. B. and Vasan R. S.
(2005). Relations of serum uric acid to longitudinal blood pressure tracking and hypertension
incidence, Hypertension, 45, no. 1, p. 28–33,.
20- Fang, J. and Alderman, M H. (2000). Serum uric acid and cardiovascular mortality: the
NHANES I epidemiologic follow-up study, 1971–1992. Journal of the American Medical
Association, 283, no. 18, p. 2404–2410.
21- Chonchol, M., Shlipak MG., Katz R. et al., (2007). Relationship of uric acid with progression
of kidney disease. American Journal of Kidney Diseases, 50, no. 2, p.
239–247.
22- Shankar, A., Klein, BEK., Nieto, FJ. and Klein R. (2008). Association between serum
uric acid level and peripheral arterial disease, Atherosclerosis. 196, no. 2, p. 749–755.
23- Dehghan, A., Hoek, MV., Sijbrands, EJG., Hofman, A. and Witteman JCM. (2008).
High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care, 31, no. 2,
p. 361–362.
24- Chien, KL., Chen, MF., Hsu HC. et al., (2008). Plasma uric acid and the risk of type 2
diabetes in a Chinese community. Clinical Chemistry, 54, no. 2, p. 310–316.
25- Kramer, CK., Mühlen, DV., Jassal, SK. and Barrett-Connor E. (2009). Serum uric acid
levels improve prediction of incident type 2 diabetes in individuals with impaired fasting
glucose. The Rancho Bernardo Study,” Diabetes Care, 32, no. 7, p. 1272–1273.
26- Nakanishi, N., Okamoto, M., Yoshida, H., Matsuo, Y., Suzuki K. and Tatara K. (2003).
Serum uric acid and risk for development of hypertension and impaired fasting glucose
or Type II diabetes in Japanese male office workers. European Journal of Epidemiology,
18, no. 6, p. 523–530.
27- Kodama, S., Saito, K., Yachi, Y. et al. (2009). Association between serum uric acid and
development of type 2 diabetes. Diabetes Care, 32, no. 9, p. 1737–1742.
28- Modan, M., Halkin, H., Karasik, A. and Lusky, A. (1987). Elevated serum uric acid—a
facet of hyperinsulinaemia. Diabetologia, 30, no. 9, p. 713–718.
29- Taniguchi, Y., Hayashi, T., Tsumura, K., Endo, G., Fujii, S. and Okada K. (2001).
Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the
Osaka health survey. Journal of Hypertension, 19, no. 7, p. 1209–1215.
30- Oda, E., Kawai, R., Sukumaran, V. and Watanabe, K. (2009). Uric acid is positively
associated with metabolic syndrome but negatively associated with diabetes in Japanese
men. Internal Medicine, 48, no. 20, pp. 1785–1791.
31- Nan, H., Dong, Y., Gao, W., Tuomilehto, J. and Qiao Q. ( 2007). Diabetes associated
with a low serum uric acid level in a general Chinese population. Diabetes Research
and Clinical Practice, 76, no. 1, p. 68–74.
32- Blagosklonnaya, MV., Shlyakhto, E. V. and Krasilnikova, EI. (2003). Trunk. Obesity
and insulin resistance a key element of the chain of metabolic cardiovascular syndrome.
Diabetes, 1, p. 12-15.
33- Zimmet, P., Shaw, J. and Alberti, G. (2003). Preventing type 2 diabetes and the
dysmetabolic syndrome in the real world: a realistic view. Diabetic Medicine, 20 (9), p.
693-702.
34- Foster, JF. and Sterman, MD. (1956), Conformation Changes in Bovine Plasma Albumin
Associated with Hydrogen Ion and Urea Binding. II. Hydrogen Ion Titration
Curves J. Am. Chem. Soc., 78 (15), pp 3656–3660, DOI: 10.1021/ja01596a027
35- Gall, WE., Beebe, K., Lawton, KA., Adam, KP., Mitchell, MW., Nakhle, PJ., Ryals,
JA., Milburn, MV., Nannipieri, M., Camastra, S., Natali A. and Ferrannini E. (2010).
RISC Study Group. alpha-hydroxybutyrate is an early biomarker of insulin resistance
and glucose intolerance in a nondiabetic population. PLoS One. 5(5):e10883. doi:
10.1371/journal.pone.0010883.
36- Ferrannini, E., Natali, A., Camastra, S., Nannipieri, M, Mari A., Adam KP.,
MilburnMV., Kastenmüller, G., Adamski J., Tuomi, T., Lyssenko, V, Groop, L. and
Gall, WE. (2013). Early metabolic markers of the development of dysglycemia and
type 2 diabetes and their physiological significance. Diabetes. 62(5), p.1730-7. doi:
10.2337/db12-0707.
37- Laios, K., Karamanou, M,, Saridaki , Z. and Androutsos G.. (2012) Aretaeus of
Cappadocia and the first description of diabetes. Hormones, 11(1), p. 109-113.